Hemab Therapeutics Holdings, Inc.’s Lock-Up Period To End Tomorrow (NASDAQ:COAG)

Hemab Therapeutics’ (NASDAQ:COAG) lock-up period will end on Wednesday, October 28th. Hemab Therapeutics had issued 16,750,000 shares in its public offering on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group lifted their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Weiss Ratings cut shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. Rodman & Renshaw started coverage on shares of Hemab Therapeutics in a research report on Monday, October 12th. They set a “buy” rating and a $56.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Hemab Therapeutics in a report on Thursday, October 15th. They set an “overweight” rating and a $70.00 price target for the company. Finally, HC Wainwright lifted their price objective on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $54.71.

Hemab Therapeutics Trading Up 4.7%

Shares of COAG opened at $36.02 on Tuesday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42. The firm has a 50 day simple moving average of $39.22.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). Equities analysts predict that Hemab Therapeutics will post -3.10 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in Hemab Therapeutics in the second quarter worth $19,226,000. Braidwell LP acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $5,877,000. State Street Corp acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $2,825,000. Opaleye Management Inc. acquired a new position in shares of Hemab Therapeutics during the second quarter valued at about $1,750,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Hemab Therapeutics during the 2nd quarter worth about $688,000.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.